Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLORIA phage therapy study in Staphylococcus aureus prosthetic joint infection treated by DAIR
2024-516555-40-00Phase 2Authorised
- Sponsor
- Phagenesis
- Start
- Mar 2025
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of PP1493 and PP1815 in periprosthetic joint infection (PJI) (2 arms), sponsored by Phagenesis. Primary endpoints: Incidence of serious adverse events and Clinical cure rate. Planned start Mar 2025; status: authorised.
02
Drugs
PP1493PP1815
03
Conditions
periprosthetic joint infection (PJI)
Beyond the preview
Go deeper on 2024-516555-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516555-40-00.